PriceTargets.com logo

Global Blood Therapeutics - GBT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$68.49 As of 11/2/2022 01:00 AM ET
+0 (0.00%)
Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $68.49.

This chart shows the closing price for GBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Global Blood Therapeutics. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/21/2022Cantor FitzgeraldReiterated RatingNeutral
8/15/2022GuggenheimBoost Target$72.00
8/15/2022WedbushDowngradeNeutral
8/15/2022Truist FinancialDowngradeHold
8/15/2022OppenheimerDowngradeMarket Perform
8/9/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
8/9/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$68.50
8/9/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$66.00 ➝ $68.50
8/9/2022CowenDowngradeMarket Perform$67.00 ➝ $68.50
8/8/2022WedbushReiterated RatingOutperform ➝ Neutral
8/8/2022Stifel NicolausReiterated RatingBuy ➝ Hold
8/8/2022William BlairDowngradeOutperform ➝ Market Perform
8/8/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$40.00 ➝ $72.00
6/28/2022JPMorgan Chase & Co.Lower TargetNeutral$39.00 ➝ $36.00
6/20/2022WedbushSet Target$74.00
5/5/2022OppenheimerLower Target$86.00 ➝ $71.00
4/28/2022Cantor FitzgeraldInitiated CoverageBuy$75.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/28/2022WedbushReiterated RatingOutperform
2/28/2022Morgan StanleyBoost TargetEqual Weight$28.00 ➝ $31.00
2/24/2022HC WainwrightReiterated RatingBuy$75.00
2/24/2022CowenLower Target$72.00 ➝ $67.00
2/24/2022OppenheimerLower TargetOutperform$92.00 ➝ $86.00
12/21/2021Leerink PartnersLower TargetOutperform$56.00 ➝ $53.00
12/14/2021Leerink PartnersBoost TargetOutperform$54.00 ➝ $56.00
12/7/2021William BlairUpgradeMarket Perform ➝ Outperform
11/5/2021Royal Bank of CanadaLower TargetOutperform$66.00 ➝ $64.00
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$68.00
9/8/2021WedbushReiterated RatingBuy
8/4/2021Truist FinancialUpgradeBuy$45.00 ➝ $50.00
8/4/2021Piper SandlerLower TargetNeutral$45.00 ➝ $40.00
6/28/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00 ➝ $36.00
5/7/2021Cantor FitzgeraldLower TargetOverweight$120.00 ➝ $110.00
5/6/2021Piper SandlerLower Target$50.00 ➝ $45.00
5/6/2021Roth CapitalLower TargetBuy$128.00 ➝ $124.00
4/14/2021Leerink PartnersInitiated CoverageOutperform$54.00
3/11/2021Wolfe ResearchInitiated CoverageOutperform$67.00
2/25/2021William BlairDowngradeOutperform ➝ Market Perform
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$75.00 ➝ $50.00
12/16/2020Morgan StanleyLower TargetEqual Weight$67.00 ➝ $45.00
12/15/2020HC WainwrightReiterated RatingBuy$75.00
12/8/2020William BlairReiterated RatingBuy
12/3/2020Royal Bank of CanadaInitiated CoverageOutperform$75.00
11/18/2020Cantor FitzgeraldLower TargetOverweight$133.00 ➝ $120.00
11/9/2020Truist FinancialLower Target$78.00 ➝ $55.00
11/6/2020Morgan StanleyLower TargetEqual Weight$68.00 ➝ $67.00
11/6/2020Roth CapitalLower TargetBuy$131.00 ➝ $128.00
11/6/2020Stifel NicolausLower TargetBuy$120.00 ➝ $101.00
11/6/2020Piper SandlerBoost TargetOverweight$75.00 ➝ $120.00
11/6/2020OppenheimerLower TargetOutperform$102.00 ➝ $92.00
11/6/2020Raymond JamesDowngradeOutperform ➝ Market Perform
10/13/2020Morgan StanleyLower TargetEqual Weight$75.00 ➝ $68.00
10/6/2020Evercore ISIInitiated CoverageOutperform$102.00
8/25/2020WedbushBoost Target$145.00 ➝ $152.00
8/24/2020Raymond JamesInitiated CoverageOutperform$115.00
8/6/2020HC WainwrightReiterated RatingBuy$150.00
8/6/2020Stifel NicolausBoost TargetBuy$113.00 ➝ $118.00
7/29/2020Piper SandlerReiterated RatingBuy$120.00
7/20/2020Roth CapitalInitiated CoverageBuy$129.00
7/13/2020Bank of AmericaInitiated CoverageBuy$92.00
7/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $103.00
6/25/2020HC WainwrightReiterated RatingBuy$150.00
6/23/2020WedbushReiterated RatingBuy$145.00
6/15/2020OppenheimerReiterated RatingBuy$101.00
6/12/2020Wells Fargo & CompanyReiterated RatingBuy
5/12/2020WedbushReiterated RatingBuy$145.00
5/7/2020Cantor FitzgeraldBoost Target$105.00 ➝ $130.00
5/7/2020NomuraReiterated RatingBuy$112.00
5/7/2020Wells Fargo & CompanyBoost TargetOverweight$122.00 ➝ $133.00
5/7/2020OppenheimerBoost TargetOutperform$88.00 ➝ $101.00
5/7/2020Morgan StanleyBoost TargetEqual Weight$70.00 ➝ $75.00
4/27/2020Stifel NicolausInitiated CoverageBuy$112.00
4/15/2020Morgan StanleyLower TargetEqual Weight$71.00 ➝ $70.00
3/19/2020WedbushReiterated RatingBuy$145.00
3/18/2020OppenheimerLower Target$100.00 ➝ $88.00
(Data available from 3/13/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/12/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/11/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/13/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Global Blood Therapeutics logo
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $68.49
Low: $68.49
High: $68.49

50 Day Range

MA: $68.47
Low: $68.07
High: $68.49

52 Week Range

Now: $68.49
Low: $21.65
High: $73.02

Volume

74 shs

Average Volume

2,065,836 shs

Market Capitalization

$4.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: StockNews.com.
View the latest analyst ratings for GBT.

What is the current price target for Global Blood Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.

What is the current consensus analyst rating for Global Blood Therapeutics?

Global Blood Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GBT.

What other companies compete with Global Blood Therapeutics?

Other companies that are similar to Global Blood Therapeutics include Teva Pharmaceutical Industries, Genmab A/S, United Therapeutics, Intra-Cellular Therapies and BioMarin Pharmaceutical. Learn More about companies similar to Global Blood Therapeutics.

How do I contact Global Blood Therapeutics' investor relations team?

Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 741-7700 and its investor relations email address is investor@gbt.com. The official website for Global Blood Therapeutics is www.gbt.com. Learn More about contacing Global Blood Therapeutics investor relations.